vs
Pebblebrook Hotel Trust（PEB）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Pebblebrook Hotel Trust的季度营收约是Bio-Techne的1.2倍（$345.7M vs $295.9M），Bio-Techne净利率更高（12.8% vs -5.3%，领先18.2%），Pebblebrook Hotel Trust同比增速更快（7.9% vs -6.4%），过去两年Bio-Techne的营收复合增速更高（4.2% vs -6.7%）
Pebblebrook Hotel Trust是一家公开上市的房地产投资信托，主要在美国核心城市及休闲目的地持有、运营并投资高端、奢华及精品酒店物业，服务商务与休闲旅客，聚焦高需求市场以推动长期价值增长。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
PEB vs TECH — 直观对比
营收规模更大
PEB
是对方的1.2倍
$295.9M
营收增速更快
PEB
高出14.3%
-6.4%
净利率更高
TECH
高出18.2%
-5.3%
两年增速更快
TECH
近两年复合增速
-6.7%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $345.7M | $295.9M |
| 净利润 | $-18.4M | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | — | 18.4% |
| 净利率 | -5.3% | 12.8% |
| 营收同比 | 7.9% | -6.4% |
| 净利润同比 | 42.9% | 68.3% |
| 每股收益（稀释后） | $-0.26 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PEBTECH
| Q1 26 | $345.7M | — | ||
| Q4 25 | $349.0M | $295.9M | ||
| Q3 25 | $398.7M | — | ||
| Q2 25 | $407.5M | $317.0M | ||
| Q1 25 | $320.3M | $316.2M | ||
| Q4 24 | $337.6M | $297.0M | ||
| Q3 24 | $404.5M | $289.5M | ||
| Q2 24 | $397.1M | $306.1M |
净利润PEBTECH
| Q1 26 | $-18.4M | — | ||
| Q4 25 | $-17.9M | $38.0M | ||
| Q3 25 | $-33.1M | — | ||
| Q2 25 | $18.1M | $-17.7M | ||
| Q1 25 | $-32.9M | $22.6M | ||
| Q4 24 | $-50.5M | $34.9M | ||
| Q3 24 | $43.7M | $33.6M | ||
| Q2 24 | $30.9M | $40.6M |
毛利率PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
营业利润率PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 18.4% | ||
| Q3 25 | -2.6% | — | ||
| Q2 25 | 12.9% | -7.5% | ||
| Q1 25 | -2.3% | 12.2% | ||
| Q4 24 | -6.7% | 16.0% | ||
| Q3 24 | 11.6% | 13.8% | ||
| Q2 24 | 15.4% | 15.0% |
净利率PEBTECH
| Q1 26 | -5.3% | — | ||
| Q4 25 | -5.1% | 12.8% | ||
| Q3 25 | -8.3% | — | ||
| Q2 25 | 4.4% | -5.6% | ||
| Q1 25 | -10.3% | 7.1% | ||
| Q4 24 | -15.0% | 11.7% | ||
| Q3 24 | 10.8% | 11.6% | ||
| Q2 24 | 7.8% | 13.3% |
每股收益（稀释后）PEBTECH
| Q1 26 | $-0.26 | — | ||
| Q4 25 | $-0.22 | $0.24 | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $0.06 | $-0.11 | ||
| Q1 25 | $-0.37 | $0.14 | ||
| Q4 24 | $-0.47 | $0.22 | ||
| Q3 24 | $0.24 | $0.21 | ||
| Q2 24 | $0.16 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $196.2M | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $2.4B | $2.0B |
| 总资产 | $5.3B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PEBTECH
| Q1 26 | $196.2M | — | ||
| Q4 25 | $184.2M | $172.9M | ||
| Q3 25 | $223.2M | — | ||
| Q2 25 | $256.1M | $162.2M | ||
| Q1 25 | $208.1M | $140.7M | ||
| Q4 24 | $206.7M | $177.5M | ||
| Q3 24 | $134.0M | $187.5M | ||
| Q2 24 | $101.7M | $152.9M |
总债务PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $260.0M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $346.0M | ||
| Q1 25 | $2.2B | $330.0M | ||
| Q4 24 | $2.2B | $300.0M | ||
| Q3 24 | $2.2B | $300.0M | ||
| Q2 24 | $2.2B | $319.0M |
股东权益PEBTECH
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $2.0B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | $1.9B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.7B | $2.1B | ||
| Q3 24 | $2.8B | $2.1B | ||
| Q2 24 | $2.7B | $2.1B |
总资产PEBTECH
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.3B | $2.5B | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $5.7B | $2.6B | ||
| Q1 25 | $5.7B | $2.6B | ||
| Q4 24 | $5.7B | $2.7B | ||
| Q3 24 | $5.7B | $2.7B | ||
| Q2 24 | $5.7B | $2.7B |
负债/权益比PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | 0.86× | 0.13× | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.85× | 0.18× | ||
| Q1 25 | 0.85× | 0.16× | ||
| Q4 24 | 0.83× | 0.14× | ||
| Q3 24 | 0.80× | 0.14× | ||
| Q2 24 | 0.80× | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | $114.5M | — |
| 自由现金流率自由现金流/营收 | 33.1% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | $249.7M | — | ||
| Q3 25 | $77.6M | — | ||
| Q2 25 | $90.5M | $98.2M | ||
| Q1 25 | $50.3M | $41.1M | ||
| Q4 24 | $275.0M | $84.3M | ||
| Q3 24 | $76.1M | $63.9M | ||
| Q2 24 | $83.7M | $75.5M |
自由现金流PEBTECH
| Q1 26 | $114.5M | — | ||
| Q4 25 | $152.3M | — | ||
| Q3 25 | $6.8M | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | $146.3M | $77.5M | ||
| Q3 24 | $-24.8M | $54.7M | ||
| Q2 24 | — | $57.5M |
自由现金流率PEBTECH
| Q1 26 | 33.1% | — | ||
| Q4 25 | 43.6% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | 43.3% | 26.1% | ||
| Q3 24 | -6.1% | 18.9% | ||
| Q2 24 | — | 18.8% |
资本支出强度PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | 27.9% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | 38.1% | 2.3% | ||
| Q3 24 | 24.9% | 3.2% | ||
| Q2 24 | — | 5.9% |
现金转化率PEBTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.01× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 1.74× | 1.90× | ||
| Q2 24 | 2.70× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PEB
| Room | $214.5M | 62% |
| Food and beverage | $91.1M | 26% |
| Other | $40.0M | 12% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
